非酒精性脂肪性肝病的同质性和异质性

李晓鹤; 魏来

doi:10.3969/j.issn.1001-5256.2018.12.001

非酒精性脂肪性肝病的同质性和异质性

DOI: 10.3969/j.issn.1001-5256.2018.12.001

李晓鹤,
魏来

北京大学人民医院北京大学肝病研究所

详细信息

中图分类号: R575
计量
- 文章访问数: 1437
- HTML全文浏览量: 38
- PDF下载量: 469
- 被引次数: 0
出版历程
- 出版日期: 2018-12-20

Heterogeneity and homogeneity of nonalcoholic fatty liver disease

Li XiaoHe,
Wei Lai

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)已经成为世界和我国流行最高的肝脏疾病。NAFLD在发病机制、病理学、临床表型等方面具有异质性。在发病机制方面,至少包括代谢/肥胖因素和基因多态性的因素;在病理学方面,成人NAFLD的肝纤维化表现为非典型的纤维化和窦纤维化,而儿童的NAFLD患者的肝纤维化在早期主要表现为汇管区纤维化,部分表现为小叶纤维化;在临床表型方面,NAFLD又可以表现为伴或不伴有糖尿病、伴或不伴有肥胖。这些异质性提示临床诊断、治疗和治疗效果评价的策略与方法不同。
- 非酒精性脂肪性肝病 /
- 儿童 /
- 成年人 /
- 述评
Abstract: Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in China and the world. However, heterogeneity exists in the pathogenesis, pathology, and clinical phenotype of NAFLD. Metabolism/obesity and gene polymorphisms are involved in the pathogenesis of NAFLD. As for pathology, NAFLD in adults manifests as atypical fibrosis and sinus fibrosis, while NAFLD in children manifests as fibrosis in the portal area and lobular fibrosis in early stage. As for clinical phenotype, some patients may have diabetes or obesity. Such heterogeneity suggests that there are different strategies and methods for clinical diagnosis, treatment, and outcome evaluation.
- non-alcoholic fatty liver disease /
- child /
- adult /
- editorial

HTML全文

参考文献(19)

[1] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40 (12) :1461-1465.

[2] VICTOR RG, HALEY RW, WILLETT DL, et al, Dallas Heart Study Investigators. The Dallas Heart Study:A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health[J]. Am J Cardiol, 2004, 93 (12) :1473-1480.

[3] SPELIOTES EK. Thwart your destiny; effect of nonacoholic fatty liver disease genes on steatosis, liver injury and cirrhosis varies by body mass index[J]. Hepatology, 2018, 68 (1) :372-374.

[4] YKI-JRVINEN H, LUUKKONEN PK. Heterogeneity of non-alcoholic fatty liver disease[J]. Liver Int, 2015, 35 (12) :2498-2500.

[5] SKOIEN R, RICHARDSON MM, JONSSON JR, et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways[J]. Liver Int, 2013, 33 (4) :624-632.

[6] LIU F, ZHAO JM, RAO HY, et al. Second harmonic generation reveals subtle fibrosis differences in adult and pediatric nonalcoholic fatty liver disease[J]. Am J Clin Pathol, 2017, 148 (6) :502-512.

[7] YOUNOSSI Z, HENRY L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality[J]. Gastroenterology, 2016, 150:1778-1785.

[8] KOEHLER EM, PLOMPEN EP, SCHOUTEN JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population:The Rotterdam study[J]. Hepatology, 2016, 63 (1) :138-147.

[9] KWOK R, CHOI KC, WONG GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J].Gut, 2016, 65 (8) :1359-1368.

[10] SOOKOIAN S, PIROLA CJ. Systematic review with meta-analysis:The significance of histological disease severity in lean patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2018, 47 (1) :16-25.

[11] KUMAR R, MOHAN S. Non-alcoholic fatty liver disease in lean subjects:Characteristics and implications[J]. J Clin Transl Hepatol, 2017, 5 (3) :216-223.

[12] European Association for the Study of the Liver (EASL) ; European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO) . EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. J Hepatol, 2016, 64 (6) :1388-1402.

[13] VAJRO P, LENTA S, SOCHA P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents:Position paper of the ESPGHAN Hepatology Committee[J]. J Pediatr Gastroenterol Nutr, 2012, 54 (5) :700-713.

[14] VOS MB, ABRAMS SH, BARLOW SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children:Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) [J]. J Pediatr Gastroenterol Nutr, 2017, 64 (2) :319-334.

[15] JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2018.[Epub ahead of print]

[16] WILDMAN-TOBRINER B, MIDDLETON MM, MOYLAN CA, et al.Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155 (5) :1428-1435.

[17] HSU C, CAUSSY C, IMAJO K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease:A systematic review and pooled analysis of individual participants[J]. Clin Gastroenterol Hepatol, 2018.[Epub ahead of print]

[18] ROMERO-GMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet, physical activity and exercise[J]. J Hepatol, 2017, 67 (4) :829-846.

[19] KONERMAN MA, JONES JC, HARRISON SA. Pharmacotherapy for NASH:Current and emerging[J]. J Hepatol, 2018, 68 (2) :362-375.

施引文献

资源附件(0)

访问统计